August 21, 2013Open Access
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Key Points
Key points are not available for this paper at this time.
Abstract
Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Development; UNIFI ClinicalTrials.gov number, NCT02407236.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Brian G. Feagan
Semmelweis University
Paul Rutgeerts
University of Leeds
Bruce E. Sands
Statens Serum Institut
Journals
New England Journal of Medicine
Actions
Institutions
University of California, San Diego
University of Toronto
University of Chicago
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...